Ginkgo Bioworks and Twist Bioscience both operate at the intersection of synthetic biology, laboratory tools, and the growing artificial intelligence (AI) push in drug discovery, yet they pursue very different business models. This stock comparison is most relevant for investors and traders evaluating how two AI-adjacent life-sciences names stack up on growth, profitability, valuation, and market positioning. Ginkgo has repositioned itself around autonomous laboratories after divesting its biosecurity business, while Twist has emerged as a high-multiple supplier of synthetic DNA. Understanding their relative performance and sentiment can help readers weigh which profile better fits current market conditions.
DNA, or Ginkgo Bioworks Holdings, has historically operated as a synthetic-biology platform, helping clients engineer cells for applications in pharmaceuticals, agriculture, and industrial chemicals. In recent quarters, the company has pivoted sharply toward autonomous laboratories, including its Nebula facility and its Cloud Lab services, following the divestiture of its biosecurity business. This restructuring has reframed Ginkgo as a provider of lab automation and biological data services for partners ranging from large pharmaceutical companies to frontier AI developers.
Recent market activity has been notably volatile. Ginkgo's shares have experienced sharp swings, with analysts highlighting above-average volatility relative to the broader market. The company continues to report declining revenue and net losses, though its losses have narrowed as restructuring-driven cost cuts take hold. Analysts remain cautious, with several maintaining sell ratings and reduced price targets citing limited visibility into how quickly the autonomous-lab strategy will convert into sustainable revenue. Sentiment has been shaped by early contract wins, such as an autonomous-lab sale to a major pharmaceutical customer, offset by ongoing cash burn and questions around monetization timelines.
TWST, or Twist Bioscience Corporation, manufactures synthetic DNA on a proprietary silicon-based platform, supplying genes, gene fragments, oligos, and variant libraries used in synthetic biology, next-generation sequencing (NGS, a method for reading DNA sequences at scale), and drug discovery. The company has positioned itself as a key enabler of AI-driven biological research, providing the physical DNA that computer-designed experiments require.
Recent market activity has been dynamic. Twist has reported consecutive quarters of revenue growth, with AI-related drug-discovery sales expanding rapidly year over year, and it has reached adjusted EBITDA breakeven on a quarterly basis. Its shares have delivered strong returns over the trailing year, though the stock has also been subject to sharp pullbacks tied to guidance nuances and a short-seller report questioning the depth of certain AI partnerships. The stock trades at a substantial premium on a price-to-sales basis, reflecting both genuine growth and elevated investor expectations.
For investors seeking a systematic approach to navigating names like these, Tickeron's Trending AI Robots page curates a selection of the platform's hundreds of AI trading bots, which collectively trade thousands of different tickers. Rather than listing every available strategy, this section highlights only the bots best suited to current market conditions. Each bot operates with its own trading style, strategy, timeframe, performance statistics, and universe of tickers, allowing users to match an automated approach to their individual objectives. Readers exploring the page can review performance metrics and positioning across a range of automated strategies to see how AI-driven systems are currently navigating the market.
The core contrast between these two companies is growth versus transformation. Twist Bioscience is an established supplier with a proven, scalable revenue engine, posting double-digit growth and improving margins, but it is priced for continued execution at roughly 20 times trailing sales. Ginkgo Bioworks, by contrast, is earlier in a strategic pivot, with revenue still contracting and profitability not yet in sight, leaving its valuation more dependent on the narrative around autonomous labs.
Risk profiles also differ. Ginkgo's shares exhibit unusually high volatility, and its thesis hinges on successfully monetizing a new business model before cash reserves tighten. Twist's primary risk is valuation-related: after a rapid rerating, its shares are sensitive to any slowdown in growth expectations, as evidenced by recent guidance-driven declines and short-seller scrutiny. On sector exposure, both benefit from the AI-in-biotech theme, but Twist generates more direct, recurring revenue from that demand today, while Ginkgo's AI linkage is more prospective.
On a relative basis, Tickeron's AI would likely favor TWST over DNA in the current environment. Twist demonstrates stronger trend consistency, a multi-quarter growth record, improving margin trajectory, and a more established revenue base, all of which support more stable market positioning. Ginkgo offers a higher-risk, higher-uncertainty profile, with revenue still declining and profitability farther out. While Twist's valuation introduces its own downside risk, its observable fundamentals and momentum provide a comparatively more reliable setup. This assessment reflects current data and could shift as either company's catalysts evolve.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
DNA saw its Momentum Indicator move below the 0 level on November 11, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned negative. In 78 of the 86 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for DNA turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 49 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
DNA moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for DNA crossed bearishly below the 50-day moving average on November 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for DNA entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +24.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where DNA advanced for three days, in 209 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.809) is normal, around the industry mean (3.596). P/E Ratio (-2.258) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (3.397) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. DNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
TWST saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 02, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 43 instances where the indicator turned negative. In 39 of the 43 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TWST as a result. In 60 of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.
TWST moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for TWST crossed bearishly below the 50-day moving average on October 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TWST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
TWST broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for TWST entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +10.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where TWST advanced for three days, in 235 of 291 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.967) is normal, around the industry mean (3.596). P/E Ratio (-54.166) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (20.243) is also within normal values, averaging (443.347).
The Tickeron Seasonality Score of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. TWST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 87 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TWST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
TWST | ||
|---|---|---|
OUTLOOK RATING 1..100 | 74 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 5 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 97 | |
PRICE GROWTH RATING 1..100 | 35 | |
P/E GROWTH RATING 1..100 | 87 | |
SEASONALITY SCORE 1..100 | 34 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| DNA | TWST | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 2 days ago 81% | 2 days ago 87% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 79% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 88% | 2 days ago 86% |
| TrendMonth ODDS (%) | 2 days ago 88% | 2 days ago 84% |
| Advances ODDS (%) | 13 days ago 84% | 4 days ago 81% |
| Declines ODDS (%) | 2 days ago 90% | 2 days ago 86% |
| BollingerBands ODDS (%) | N/A | 2 days ago 83% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 85% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DNA’s FA Score shows that 0 FA rating(s) are green while TWST’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DNA’s TA Score shows that 2 TA indicator(s) are bullish while TWST’s TA Score has 2 bullish TA indicator(s).
DNA (@Biotechnology) experienced а -22.37% price change this week, while TWST (@Biotechnology) price change was -7.42% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -11.58%. For the same industry, the average monthly price growth was -18.26%, and the average quarterly price growth was -28.15%.
DNA is expected to report earnings on Mar 04, 2027.
TWST is expected to report earnings on Jan 29, 2027.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, DNA has been loosely correlated with TWST. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if DNA jumps, then TWST could also see price increases.
| Ticker / NAME | Correlation To DNA | 1D Price Change % | ||
|---|---|---|---|---|
| DNA | 100% | -9.02% | ||
| TWST - DNA | 63% Loosely correlated | -7.44% | ||
| RXRX - DNA | 61% Loosely correlated | -9.93% | ||
| VCYT - DNA | 58% Loosely correlated | +0.36% | ||
| ABSI - DNA | 53% Loosely correlated | -7.97% | ||
| NTLA - DNA | 53% Loosely correlated | +5.04% | ||
More | ||||